Viral Vector and Plasmid DNA Manufacturing Market-Market Insights

Viral vectors are used as carriers to transfer the genetic material into other living organisms. The viral vector production can be done in two types of culture system such as suspension cell cultures and adherent-cell systems. For large-scale manufacturing of viral vectors, the conventional lab processes of adherent-cell systems such as multilayer flasks, hollow-fiber technologies, T-flasks, and roller bottles experience challenges in scaling up such as larger space requirement and increased manual workload.

Plasmid DNA is extrachromosomal DNA found in bacteria, which is generally circular in shape. The genetic engineers use plasmid DNA to create recombinant DNA, in order to transfer genetic material in other organisms. Plasmid DNAs are limited by some biological barriers such as endosomal attack, renal clearance, and degradation by serum endonucleases. Moreover, for direct gene transfer into humans, good manufacturing practice (GMP)-grade plasmid DNA is mandatory. Therefore, around 70% of gene therapy clinical trials, to date, have involved viral vector systems.

The global viral vector and plasmid DNA manufacturing market is expected to be valued at US$ 427.2 million in 2019, and is expected to exhibit a CAGR of 22.8% over the forecast period (2019-2027).

Figure 1. Global Viral Vector and Plasmid DNA Manufacturing Market Value (US$ Mn), by Region, 2019

Viral Vector & Plasmid DNA Manufacturing  | Coherent Market Insights

Source: Coherent Market Insights Analysis (2020)

Increasing number of gene therapy patients is expected to propel the market growth over the forecast period

The increasing number of patients opting for gene therapy for treating diseases such as cancer, cystic fibrosis, heart disease, diabetes, hemophilia, and AIDS is expected to drive growth of the viral vector and plasmid DNA manufacturing market over the forecast period. For instance, Adeno-associated AAV2 vectors carrying therapeutic gene (RPE65) intra-retinal injection lead to improve vision of individuals suffering from Leber’s Congenital Amaurosis.

Moreover, several clinical trials are being conducted on viral vectors and plasmid DNA manufacturing that are focused on the potential of gene therapy. According to a data published by the Journal of Gene Medicine, in 2017, around 2,600 gene therapy clinical trials are ongoing, have been completed or approved in 36 countries. Moreover, countries, where the trials were conducted include the U.S., U.K., Australia, Canada, China, France, Germany, Japan Switzerland, the Netherlands, and others.

Figure 2. Global Viral Vector and Plasmid DNA Manufacturing Market Share (%), by Therapeutic Application, 2027

Viral Vector & Plasmid DNA Manufacturing  | Coherent Market Insights

Source: Coherent Market Insights Analysis (2020)

Increasing technological advancements in the manufacturing of viral vector and plasmid DNA is expected to drive the market growth over the forecast period

The rising demand for viral vector and plasmid DNA for gene therapies has led major players in the market to launch new and technologically advanced programs and devices to scale up the production of viral vectors and plasmid DNA. For instance, in April 2018, GE Healthcare Life Sciences launched a prefabricated, modular bioprocessing facility KUBio BSL 2 for production of viral vector-based vaccines, oncolytic virus, and cell and gene therapies.

Moreover, government funding is increasing for development of new technologies and production facilities of viral vector. For instance, in 2018, Innovate UK, Department for Business, Energy & Industrial awarded the Industrial Strategy Challenge Fund of US$ 3.4 million capital to Cobra Biologics for infrastructure investment to expand manufacturing capabilities and commercialization of DNA and viral vectors products. Thus, rising research and development funding from government organization is expected to drive growth of the market over the forecast period.

However, the manufacturing processes of viral vectors is expensive and time consuming. Large scale production of recombinant viral vector is a complex process and is considered as a major challenge and large barrier for commercialization. Therefore, increasing difficulties in viral vector manufacturing capacity is expected to hinder growth of the global viral vectors and plasmid DNA manufacturing market.

Key Players

Major players operating in the global viral vector and plasmid DNA manufacturing market include Lonza Group AG, FinVector Vision Therapies, Cobra Biologics and Pharmaceutical Services, Sigma-Aldrich Co. LLC, VGXI, Inc., VIROVEK, SIRION Biotech GmbH, FUJIFILM Diosynth Biotechnologies U.S.A., Inc., Sanofi, Cell and Gene Therapy Catapult, Brammer Bio, and MassBiologics.

Viral vectors aids in transferring genetic material into target cells and therefore, used in various therapeutic areas. Viral vectors can be significantly used in vaccines development against pathogens such as Mycobacterium tuberculosis, Plasmodium falciparum, HIV, and various bio-threat targets such as filoviruses. Plasmid DNA (pDNA) is gaining traction for clinical research applications in genetic vaccination and gene therapy. It is becoming increasingly useful as novel biotechnology product for DNA vaccines and gene medicines. It can be directly used as a therapeutic agent and indirectly used for various applications such as a starting material for transient transfection to produce transient proteins and viral vector constructs. Furthermore, pDNA is used as a master-template product to support production of new and developing biopharmaceutical products and processes such as cell therapies.

Market Dynamics

Increasing approvals by regulatory authorities for novel gene therapies is expected to drive growth of the gene therapy segment. For instance, in September 2017, GeneOne Life Science, Inc., received approval from the South Korean Ministry of Food and Drug Safety (KMFDS) for an Investigational New Drug application for a Phase I/IIa study of its investigational vaccine, GLS-5300, against the Middle East Respiratory Syndrome coronavirus (MERSCoV). Moreover, in May 2019, AveXis Inc. received the U.S. Food and Drug Administration approval for its Zolgensma (onasemnogene abeparvovec-xioi), an adeno-associated virus vector-based gene therapy for the treatment of pinal muscular atrophy (SMA) in children less than two years old.

Key features of the study:

  • This report provides in-depth analysis of the global viral vector and plasmid DNA manufacturing market and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2019–2027), considering 2018 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global viral vector and plasmid DNA manufacturing market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include Lonza Group AG, FinVector Vision Therapies, Cobra Biologics and Pharmaceutical Services, Sigma-Aldrich Co. LLC, VGXI, Inc., VIROVEK, SIRION Biotech GmbH, FUJIFILM Diosynth Biotechnologies U.S.A., Inc., Sanofi, Cell and Gene Therapy Catapult, Brammer Bio, and MassBiologics.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
  • The global viral vector and plasmid DNA manufacturing market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global viral vector and plasmid DNA manufacturing market

Detailed Segmentation:

  • Global Viral Vector and Plasmid DNA Manufacturing Market, By Product Type:
    • Viral Vector
      • Retroviral Vectors
      • Adenoviral Vectors
      • Lentiviral Vectors
      • Adeno-associated Viral Vectors
      • Others
    • Plasma DNA
    • Non-viral DNA Vectors
  • Global Viral Vector and Plasmid DNA Manufacturing Market, By Therapeutic Application:
    • Cancer
    • Inherited Disorders
    • Infectious Diseases
    • Others
  • Global Viral Vector and Plasmid DNA Manufacturing Market, By End Product:
    • DNA Vaccines
    • Gene Therapy
    • Immunotherapy
    • Others
  • Global Viral Vector and Plasmid DNA Manufacturing Market, By Region:
    • North America
      • By Product Type:
        • Viral Vector
          • Retroviral Vectors
          • Adenoviral Vectors
          • Lentiviral Vectors
          • Adeno-associated Viral Vectors
          • Others
        • Plasma DNA
        • Non-viral DNA Vectors
      • By Therapeutic Application:
        • Cancer
        • Inherited Disorders
        • Infectious Diseases
        • Others
      • By End Product:
        • DNA Vaccines
        • Gene Therapy
        • Immunotherapy
        • Others
      • By Country:
        • U.S.
        • Canada
    • Latin America
      • By Product Type:
        • Viral Vector
          • Retroviral Vectors
          • Adenoviral Vectors
          • Lentiviral Vectors
          • Adeno-associated Viral Vectors
          • Others
        • Plasma DNA
        • Non-viral DNA Vectors
      • By Therapeutic Application:
        • Cancer
        • Inherited Disorders
        • Infectious Diseases
        • Others
      •  By End Product:
        • DNA Vaccines
        • Gene Therapy
        • Immunotherapy
        • Others
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Product Type:
        • Viral Vector
          • Retroviral Vectors
          • Adenoviral Vectors
          • Lentiviral Vectors
          • Adeno-associated Viral Vectors
          • Others
        • Plasma DNA
        • Non-viral DNA Vectors
      • By Therapeutic Application:
        • Cancer
        • Inherited Disorders
        • Infectious Diseases
        • Others
      • By End Product:
        • DNA Vaccines
        • Gene Therapy
        • Immunotherapy
        • Others
      • By Country:
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Product Type:
        • Connected
        • Regular Viral Vector
          • Retroviral Vectors
          • Adenoviral Vectors
          • Lentiviral Vectors
          • Adeno-associated Viral Vectors
          • Others
        • Plasma DNA
        • Non-viral DNA Vectors  
      • By Therapeutic Application:
        • Cancer
        • Inherited Disorders
        • Infectious Diseases
        • Others
      • By End Product:
        • DNA Vaccines
        • Gene Therapy
        • Immunotherapy
        • Others
      • By Country:
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Product Type:
        • Viral Vector
          • Retroviral Vectors
          • Adenoviral Vectors
          • Lentiviral Vectors
          • Adeno-associated Viral Vectors
          • Others
        • Plasma DNA
        • Non-viral DNA Vectors
      • By Therapeutic Application:
        • Cancer
        • Inherited Disorders
        • Infectious Diseases
        • Others
      • By End Product:
        • DNA Vaccines
        • Gene Therapy
        • Immunotherapy
        • Others
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Product Type:
        • Viral Vector
          • Retroviral Vectors
          • Adenoviral Vectors
          • Lentiviral Vectors
          • Adeno-associated Viral Vectors
          • Others
        • Plasma DNA
        • Non-viral DNA Vectors
      • By Therapeutic Application:
        • Cancer
        • Inherited Disorders
        • Infectious Diseases
        • Others
      • By End Product:
        • DNA Vaccines
        • Gene Therapy
        • Immunotherapy
        • Others
      • By Country/Region:
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Lonza Group AG *
      • Company Overview
      • Material Portfolio
      • Financial Performance
      • Key Highlights
      • Market Strategies
    • FinVector Vision Therapies
    • Cobra Biologics and Pharmaceutical Services
    • Sigma-Aldrich Co. LLC
    • VGXI, Inc.
    • VIROVEK
    • SIRION Biotech GmbH
    • FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
    • Sanofi
    • Cell and Gene Therapy Catapult
    • Brammer Bio
    • MassBiologics

 “*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Product Type
      • Market Snippet, By Therapeutic Application
      • Market Snippet, By End Product
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis of DROs
    • Comparative Analysis of Different Types of Viral Systems
    • Collaborations, Partnerships, And Agreements
    • Pipeline Analysis
    • New Product Launches
    • Investment Opportunities
    • Regulatory Scenario
    • Strategies For Product Development And Application Pathways
    • Brand Analysis
    • Cell & Gene Therapy Manufacturing Capacities In Europe
    • Porter’s Analysis
  4. Global Viral Vector and Plasmid DNA Manufacturing Market, By Product Type, 2016 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Viral Vector
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
        • Retroviral Vectors
        • Adenoviral Vectors
        • Lentiviral Vectors
        • Adeno-associated Viral Vectors
        • Others
    • Plasma DNA
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Non-viral DNA Vectors
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
  5. Global Viral Vector and Plasmid DNA Manufacturing Market, By Therapeutic Application, 2016 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Cancer
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Inherited Disorders
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Infectious Diseases
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
  6. Global Viral Vector and Plasmid DNA Manufacturing Market, By End Product, 2016 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • DNA Vaccines
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Gene Therapy
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Immunotherapy
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
  7. Global Viral Vector and Plasmid DNA Manufacturing Market, By Region, 2016 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, By Region, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, For Regions, 2017–2027
    • North America
      • Market Size and Forecast, By Product Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Therapeutic Application, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By End Product, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • U.S.
        • Canada
    • Latin America
      • Market Size and Forecast, By Product Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Therapeutic Application, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By End Product, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • Market Size and Forecast, By Product Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Therapeutic Application, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By End Product, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Product Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Therapeutic Application, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By End Product, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • Market Size and Forecast, By Product Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Therapeutic Application, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By End Product, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Market Size and Forecast, By Product Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Therapeutic Application, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By End Product, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country/Region, 2016 – 2027, (US$ Mn)
        • South Africa
        • Central Africa
        • North Africa
  8. Competitive Landscape
    • Heat Map Analysis
    • Market Share Analysis
      • Lonza Group AG *
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • FinVector Vision Therapies
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Cobra Biologics and Pharmaceutical Services
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Sigma-Aldrich Co. LLC
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • VGXI, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • VIROVEK
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • SIRION Biotech GmbH
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Sanofi
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Cell and Gene Therapy Catapult
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Brammer Bio
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • MassBiologics
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
    • Analyst Views
  9. Section
    • References
    • Research Methodology
    • About Us and Sales Contact

*Browse 34 market data tables and 33 figures on "Viral Vector and Plasmid DNA Manufacturing Market” - Global forecast to 2027.